{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:25:58Z","timestamp":1780338358605,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The incidence of invasive pneumococcal disease (IPD) varies depending on a number of factors, including vaccine uptake, in both children and adults, the geographic location, and local serotype prevalence. There are limited data about the burden of\u00a0<jats:italic>Streptococcus pneumoniae<\/jats:italic> (<jats:italic>Spn<\/jats:italic>), serotype distribution, and clinical characteristics of adults hospitalized due to IPD in Colombia. The objectives of this study included assessment of <jats:italic>Spn<\/jats:italic> serotype distribution, clinical characteristics, mortality, ICU admission, and the need for mechanical ventilation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was an observational, retrospective, a citywide study conducted between 2012 and 2019 in Bogot\u00e1, Colombia. We analyzed reported positive cases of IPD from 55 hospitals in a governmental pneumococcal surveillance program. Pneumococcal strains were isolated in each hospital and typified in a centralized laboratory. This is a descriptive study stratified by age and subtypes of IPD obtained through the analysis of medical records.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 310 patients with IPD were included, of whom 45.5% were female. The leading cause of IPD was pneumonia (60%, 186\/310), followed by meningitis. The most frequent serotypes isolated were 19A (13.87%, 43\/310) and 3 (11.94%, 37\/310). The overall hospital mortality rate was 30.3% (94\/310). Moreover, 52.6% (163\/310 patients) were admitted to the ICU, 45.5% (141\/310) required invasive mechanical ventilation and 5.1% (16\/310) non-invasive mechanical ventilation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pneumococcal pneumonia is the most prevalent cause of IPD, with serotypes 19A and 3 being the leading cause of IPD in Colombian adults. Mortality due to IPD in adults continues to be very high.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06769-2","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T22:08:29Z","timestamp":1634076509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Invasive pneumococcal disease burden in hospitalized adults in Bogota, Colombia"],"prefix":"10.1186","volume":"21","author":[{"given":"Paula O.","family":"Narv\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Gomez-Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan E.","family":"Alarcon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula C.","family":"Ramirez-Valbuena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian C.","family":"Serrano-Mayorga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Lozada-Arcinegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alirio","family":"Bastidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"6769_CR1","unstructured":"Centers for Disease C. Invasive Pneumococcal Disease\u2014case definition. 2017 (18\/05\/2021). https:\/\/wwwn.cdc.gov\/nndss\/conditions\/invasive-pneumococcal-disease\/case-definition\/2017\/."},{"issue":"5","key":"6769_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/adc.2010.191718","volume":"96","author":"E Randle","year":"2011","unstructured":"Randle E, Ninis N, Inwald D. Invasive pneumococcal disease. Arch Dis Child Educ Pract Ed. 2011;96(5):183\u201390. https:\/\/doi.org\/10.1136\/adc.2010.191718 (Epub 2011\/05\/11).","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"6769_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.12703\/p6-82","volume":"6","author":"C Feldman","year":"2014","unstructured":"Feldman C, Anderson R. Recent advances in our understanding of Streptococcus pneumoniae infection. F1000prime Rep. 2014;6:82. https:\/\/doi.org\/10.12703\/p6-82.","journal-title":"F1000prime Rep."},{"key":"6769_CR4","unstructured":"Centers for Disease C. Report findings\u2014Streptococcus pneumoniae 2018 (18\/05\/2021). https:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu18.html."},{"issue":"1","key":"6769_CR5","doi-asserted-by":"publisher","first-page":"e84993","DOI":"10.1371\/journal.pone.0084993","volume":"9","author":"EL Parra","year":"2014","unstructured":"Parra EL, Ramos V, Sanabria O, Moreno J. Serotype and genotype distribution among invasive Streptococcus pneumoniae isolates in Colombia, 2005\u20132010. PLoS ONE. 2014;9(1):e84993. https:\/\/doi.org\/10.1371\/journal.pone.0084993 (Epub 2014\/01\/15).","journal-title":"PLoS ONE"},{"key":"6769_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijid.2021.02.031","volume":"105","author":"DF Severiche-Bueno","year":"2021","unstructured":"Severiche-Bueno DF, Severiche-Bueno DF, Bastidas A, Caceres EL, Silva E, Lozada J, et al. Burden of invasive pneumococcal disease (IPD) over a 10-year period in Bogota, Colombia. Int J Infect Dis. 2021;105:32\u20139. https:\/\/doi.org\/10.1016\/j.ijid.2021.02.031 (Epub 2021\/02\/15).","journal-title":"Int J Infect Dis"},{"key":"6769_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.vhri.2017.04.004","volume":"14","author":"AE Bardach","year":"2017","unstructured":"Bardach AE, Rey-Ares L, Calderon Cahua M, Ciapponi A, Cafferata ML, Cormick G, et al. Burden of culture-confirmed pediatric Pneumococcal pneumonia in Latin America and the Caribbean: a systematic review and meta-analysis. Value Health Reg Issues. 2017;14:41\u201352. https:\/\/doi.org\/10.1016\/j.vhri.2017.04.004 (Epub 2017\/12\/20).","journal-title":"Value Health Reg Issues."},{"issue":"5","key":"6769_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1500245","volume":"373","author":"S Jain","year":"2015","unstructured":"Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1500245.","journal-title":"N Engl J Med"},{"issue":"4","key":"6769_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jinf.2019.07.004","volume":"79","author":"S Aliberti","year":"2019","unstructured":"Aliberti S, Cook GS, Babu BL, Reyes LF, Rodriguez AH, Sanz F, et al. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia. J Infect. 2019;79(4):300\u201311. https:\/\/doi.org\/10.1016\/j.jinf.2019.07.004 (Epub 2019\/07\/13).","journal-title":"J Infect"},{"issue":"12","key":"6769_CR10","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/s1473-3099(16)30267-5","volume":"16","author":"S Aliberti","year":"2016","unstructured":"Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, et al. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis. 2016;16(12):1364\u201376. https:\/\/doi.org\/10.1016\/s1473-3099(16)30267-5.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"6769_CR11","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","volume":"372","author":"MJ Bonten","year":"2015","unstructured":"Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against Pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1408544 (Epub 2015\/03\/19).","journal-title":"N Engl J Med"},{"issue":"4","key":"6769_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1055\/s-0040-1713003","volume":"41","author":"RG Wunderink","year":"2020","unstructured":"Wunderink RG, Feldman C. Community-acquired pneumonia: a global perspective. Semin Respir Crit Care Med. 2020;41(4):453\u20134. https:\/\/doi.org\/10.1055\/s-0040-1713003 (Epub 2020\/07\/07).","journal-title":"Semin Respir Crit Care Med."},{"issue":"9700","key":"6769_CR13","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/s0140-6736(09)61114-4","volume":"374","author":"T Van der Poll","year":"2009","unstructured":"Van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009;374(9700):1543\u201356. https:\/\/doi.org\/10.1016\/s0140-6736(09)61114-4.","journal-title":"Lancet"},{"issue":"13","key":"6769_CR14","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.vaccine.2016.02.023","volume":"34","author":"WQ Diao","year":"2016","unstructured":"Diao WQ, Shen N, Yu PX, Liu BB, He B. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: a systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496\u2013503. https:\/\/doi.org\/10.1016\/j.vaccine.2016.02.023.","journal-title":"Vaccine"},{"issue":"9","key":"6769_CR15","doi-asserted-by":"publisher","first-page":"886 e1","DOI":"10.1016\/j.amjmed.2014.05.010","volume":"127","author":"M Mirsaeidi","year":"2014","unstructured":"Mirsaeidi M, Ebrahimi G, Allen MB, Aliberti S. Pneumococcal vaccine and patients with pulmonary diseases. Am J Med. 2014;127(9):886 e1-888. https:\/\/doi.org\/10.1016\/j.amjmed.2014.05.010.","journal-title":"Am J Med"},{"key":"6769_CR16","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22341.1","author":"C Feldman","year":"2020","unstructured":"Feldman C, Anderson R. Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Res. 2020. https:\/\/doi.org\/10.12688\/f1000research.22341.1 (Epub 2020\/05\/1).","journal-title":"F1000Res"},{"issue":"5","key":"6769_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1542\/peds.2009-1405","volume":"125","author":"KA Bryant","year":"2010","unstructured":"Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, Group PCVIS. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125(5):866\u201375. https:\/\/doi.org\/10.1542\/peds.2009-1405 (Epub 2010\/05\/04).","journal-title":"Pediatrics"},{"issue":"6 Suppl 4","key":"6769_CR18","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.1016\/j.amepre.2015.09.008","volume":"49","author":"T Pilishvili","year":"2015","unstructured":"Pilishvili T, Bennett NM. Pneumococcal disease prevention among adults: strategies for the use of pneumococcal vaccines. Am J Prev Med. 2015;49(6 Suppl 4):S383\u201390. https:\/\/doi.org\/10.1016\/j.amepre.2015.09.008 (Epub 2015\/11\/23).","journal-title":"Am J Prev Med"},{"issue":"3","key":"6769_CR19","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1542\/peds.2009-3027","volume":"126","author":"SH Yeh","year":"2010","unstructured":"Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493-505. https:\/\/doi.org\/10.1542\/peds.2009-3027 (Epub 2010\/08\/25).","journal-title":"Pediatrics"},{"issue":"46","key":"6769_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","volume":"68","author":"A Matanock","year":"2019","unstructured":"Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >\/=65 years: updated recommendations of the Advisory Committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069\u201375. https:\/\/doi.org\/10.15585\/mmwr.mm6846a5 (Epub 2019\/11\/22).","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"6769_CR21","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1086\/521626","volume":"196","author":"LA Hicks","year":"2007","unstructured":"Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998\u20132004. J Infect Dis. 2007;196(9):1346\u201354. https:\/\/doi.org\/10.1086\/521626 (Epub 2007\/10\/09).","journal-title":"J Infect Dis"},{"issue":"3","key":"6769_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1473-3099(20)30489-8","volume":"21","author":"CI Agudelo","year":"2021","unstructured":"Agudelo CI, Castaneda-Orjuela C, Brandileone MCC, Echaniz-Aviles G, Almeida SCG, Carnalla-Barajas MN, et al. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006\u201317): a multicentre, retrospective observational study. Lancet Infect Dis. 2021;21(3):405\u201317. https:\/\/doi.org\/10.1016\/S1473-3099(20)30489-8 (Epub 2020\/09\/29).","journal-title":"Lancet Infect Dis"},{"issue":"38","key":"6769_CR23","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1016\/j.vaccine.2018.07.078","volume":"36","author":"C Castaneda-Orjuela","year":"2018","unstructured":"Castaneda-Orjuela C, De la Hoz-Restrepo F. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Vaccine. 2018;36(38):5766\u201373. https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.078 (Epub 2018\/08\/09).","journal-title":"Vaccine"},{"issue":"6","key":"6769_CR24","first-page":"422","volume":"33","author":"C Duarte","year":"2013","unstructured":"Duarte C, Sanabria O, Moreno J. Molecular characterization of Streptococcus pneumoniae serotype 1 invasive isolates in Colombia. Rev Panam Salud Publica. 2013;33(6):422\u20136 (Epub 2013\/08\/14).","journal-title":"Rev Panam Salud Publica"},{"issue":"5","key":"6769_CR25","doi-asserted-by":"publisher","first-page":"1000081","DOI":"10.1371\/journal.pmed.1000081","volume":"6","author":"ZB Harboe","year":"2009","unstructured":"Harboe ZB, Thomsen RW, Riis A, Valentiner-Branth P, Christensen JJ, Lambertsen L, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009;6(5):1000081. https:\/\/doi.org\/10.1371\/journal.pmed.1000081 (Epub 2009\/05\/27).","journal-title":"PLoS Med"},{"key":"6769_CR26","doi-asserted-by":"publisher","first-page":"e51208","DOI":"10.3791\/51208","volume":"84","author":"M Habib","year":"2014","unstructured":"Habib M, Porter BD, Satzke C. Capsular serotyping of Streptococcus pneumoniae using the Quellung reaction. J Vis Exp. 2014;84:e51208. https:\/\/doi.org\/10.3791\/51208 (Epub 2014\/03\/19).","journal-title":"J Vis Exp"},{"issue":"4","key":"6769_CR27","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.idc.2015.07.009","volume":"29","author":"I Yildirim","year":"2015","unstructured":"Yildirim I, Shea KM, Pelton SI. Pneumococcal disease in the era of pneumococcal conjugate vaccine. Infect Dis Clin North Am. 2015;29(4):679\u201397. https:\/\/doi.org\/10.1016\/j.idc.2015.07.009 (Epub 2015\/11\/28).","journal-title":"Infect Dis Clin North Am"},{"issue":"7","key":"6769_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):45\u201367. https:\/\/doi.org\/10.1164\/rccm.201908-1581ST (Epub 2019\/10\/02).","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"6769_CR29","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1086\/425368","volume":"39","author":"AR Tunkel","year":"2004","unstructured":"Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267\u201384. https:\/\/doi.org\/10.1086\/425368 (Epub 2004\/10\/21).","journal-title":"Clin Infect Dis"},{"issue":"11","key":"6769_CR30","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","volume":"26","author":"JL Vincent","year":"1998","unstructured":"Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793\u2013800. https:\/\/doi.org\/10.1097\/00003246-199811000-00016 (Epub 1998\/11\/21).","journal-title":"Crit Care Med"},{"key":"6769_CR31","doi-asserted-by":"crossref","unstructured":"Headley J, Theriault R, Smith TL. Independent validation of APACHE II severity of illness score for predicting mortality in patients with breast cancer admitted to the intensive care unit. Cancer. 1992;70(2):497\u2013503. https:\/\/doi.org\/10.1002\/1097-0142(19920715)70:2<497::aid-cncr2820700220>3.0.co;2-h. (Epub 1992\/07\/15).","DOI":"10.1002\/1097-0142(19920715)70:2<497::AID-CNCR2820700220>3.0.CO;2-H"},{"issue":"10","key":"6769_CR32","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/thoraxjnl-2015-206780","volume":"70","author":"A Torres","year":"2015","unstructured":"Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and\/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015;70(10):984\u20139. https:\/\/doi.org\/10.1136\/thoraxjnl-2015-206780 (Epub 2015\/07\/30).","journal-title":"Thorax"},{"issue":"1","key":"6769_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/cid\/ciy875","volume":"69","author":"DM Weinberger","year":"2019","unstructured":"Weinberger DM, Warren JL, Dalby T, Shapiro ED, Valentiner-Branth P, Slotved HC, et al. Differences in the impact of pneumococcal serotype replacement in individuals with and without underlying medical conditions. Clin Infect Dis. 2019;69(1):100\u20136. https:\/\/doi.org\/10.1093\/cid\/ciy875 (Epub 2018\/10\/16).","journal-title":"Clin Infect Dis"},{"issue":"9807","key":"6769_CR34","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(10)62225-8","volume":"378","author":"DM Weinberger","year":"2011","unstructured":"Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(10)62225-8 (Epub 2011\/04\/16).","journal-title":"Lancet"},{"key":"6769_CR35","unstructured":"Centers for Disease C, Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998\u20132003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893\u20137 (Epub 2005\/09\/16)."},{"issue":"16","key":"6769_CR36","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","volume":"294","author":"CA Lexau","year":"2005","unstructured":"Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043\u201351. https:\/\/doi.org\/10.1001\/jama.294.16.2043 (Epub 2005\/10\/27).","journal-title":"JAMA"},{"issue":"12","key":"6769_CR37","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1086\/518149","volume":"44","author":"WC Albrich","year":"2007","unstructured":"Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(12):1569\u201376. https:\/\/doi.org\/10.1086\/518149 (Epub 2007\/05\/23).","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6769_CR38","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1080\/21645515.2018.1425115","volume":"14","author":"DC Caceres","year":"2018","unstructured":"Caceres DC, Ortega-Barria E, Nieto J, DeAntonio R. Pneumococcal meningitis trends after pneumococcal conjugate vaccine introduction in Colombia: an interrupted time-series analysis. Hum Vaccin Immunother. 2018;14(5):1230\u20133. https:\/\/doi.org\/10.1080\/21645515.2018.1425115 (Epub 2018\/01\/20).","journal-title":"Hum Vaccin Immunother"},{"key":"6769_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1710411","author":"CG Moreno","year":"2020","unstructured":"Moreno CG, Imbachi LF, Leal AL, Moreno VM, Patino JA, Gutierrez IF, et al. Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogota, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10. Hum Vaccin Immunother. 2020. https:\/\/doi.org\/10.1080\/21645515.2019.1710411.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"6769_CR40","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1183\/13993003.01451-2015","volume":"47","author":"I Galanis","year":"2016","unstructured":"Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjostrom K, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47(4):1208\u201318. https:\/\/doi.org\/10.1183\/13993003.01451-2015 (Epub 2016\/01\/23).","journal-title":"Eur Respir J"},{"issue":"8","key":"6769_CR41","doi-asserted-by":"publisher","first-page":"e0201312","DOI":"10.1371\/journal.pone.0201312","volume":"13","author":"H Jiang","year":"2018","unstructured":"Jiang H, Huai Y, Chen H, Uyeki TM, Chen M, Guan X, et al. Invasive Streptococcus pneumoniae infection among hospitalized patients in Jingzhou city, China, 2010\u20132012. PLoS ONE. 2018;13(8):e0201312. https:\/\/doi.org\/10.1371\/journal.pone.0201312 (Epub 2018\/08\/21).","journal-title":"PLoS ONE"},{"issue":"31","key":"6769_CR42","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1016\/j.vaccine.2018.06.018","volume":"36","author":"WHB Demczuk","year":"2018","unstructured":"Demczuk WHB, Martin I, Desai S, Griffith A, Caron-Poulin L, Lefebvre B, et al. Serotype distribution of invasive Streptococcus pneumoniae in adults 65years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010\u20132016. Vaccine. 2018;36(31):4701\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.018 (Epub 2018\/06\/26).","journal-title":"Vaccine"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06769-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06769-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T02:01:39Z","timestamp":1634090499000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06769-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6769"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06769-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved, and the use of informed consent was waived the Institutional Review Board of the Clinica Universidad de La Sabana (2020_MED-23221). The use of informed consent was waived because this was a retrospective study, without any intervention, and used only a chart review to obtain clinical data. Local ethical guidelines were followed to carry out this project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Charles Feldman has acted on the advisory board and speaker\u2019s bureau for Pfizer and the speaker\u2019s bureau for MSD. All other authors have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1059"}}